"Lielākais gastroenteroloģijas centrs Baltijā. 2021.gadā atzīmē savu 20 gadu jubileju. Nodrošina pilnu diagnostisko un ārstniecisko pasākumu spektru gremošanas sistēmas (barības vada, kuņģa, zarnu, žultsceļu, aizkuņģa dziedzera, aknu) slimību noteikšanai un ārstēšanai. Mūsu vērtības: - profesionalitāte it visā, ko mēs darām; - jaunākās paaudzes tehnoloģijas diagnostikā un ārstniecībā; - pacientu labsajūta un komforts."

During the past decade, Digestive Diseases Center "Gastro" conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 17 clinical trials were completed, i.e. on average, 85% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 13 clinical trials were completed. i.e. 650% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Digestive Diseases Center "Gastro"" #1 sponsor was "Celgene" with 6 trials, followed by "Allergan" with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "Ferring Pharmaceuticals" with 3 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Digestive Diseases Center "Gastro"" #1 collaborator was "Cosmo Technologies Ltd" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Digestive Diseases Center "Gastro"" are "Ulcerative Colitis" (13 trials), "Crohn Disease" (5 trials), "Gastroparesis" (4 trials), "Diabetes Mellitus" (3 trials) and "Colitis, Ulcerative" (1 trials). Many other conditions were trialed in "Digestive Diseases Center "Gastro"" in a lesser frequency.

Most popular intervention types in "Digestive Diseases Center "Gastro"" are "Drug" (26 trials), "Other" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "GED-0301" (3 trials), "Ozanimod" (3 trials), "Relamorelin" (3 trials) and "Adalimumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Digestive Diseases Center "Gastro"" are 27 trials for "All" genders.

Currently, there are NaN active trials in "Digestive Diseases Center "Gastro"". undefined are not yet recruiting, 7 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Digestive Diseases Center "Gastro", undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Digestive Diseases Center "Gastro", 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".